Table 1 Baseline characteristics

From: Exploring the trimethylamine pathway in advanced chronic liver disease

 

Overall, N = 66

Compensated ACLD, N = 30

Decompensated ACLD, N = 36

p value

Gender

   

0.5

 Female

23 (35%)

9 (30%)

14 (39%)

 

Age (years)

   

0.3

 Mean (SD)

61 (9)

62 (6)

60 (10)

 

BMIa

   

0.02b

 Mean (SD)

30.0 (5.7)

31.7 (5.1)

28.4 (5.8)

 

Overweighta

49 (82%)

26 (90%)

23 (74%)

0.12

Obesitya

30 (50%)

19 (66%)

11 (35%)

0.02b

Platelet Count G/l

   

0.8

 Median (IQR)

111 (82–141)

106 (85–153)

114 (81–140)

 

Sodium mmol/l

   

0.2

 Median (IQR)

140 (137–141)

140.0 (139–141)

139.0 (135–141)

 

Creatinine (µmol/l)

   

0.3

 Median (IQR)

74 (63–86)

69 (63–79)

80 (63–88)

 

Total Bilirubin (µmol/l)

   

0.01b

 Median (IQR)

18 (12–31)

16 (10–24)

24 (14–56)

 

Albumina g/l

   

0.002b

 Median (IQR)

33 (29–36)

36 (32–38)

32 (24–35)

 

INR

   

0.02b

 Median (IQR)

1.14 (1.05–1.29)

1.10 (1.02–1.23)

1.17 (1.10–1.36)

 

Diabetes type II

39 (59%)

18 (60%)

21 (58%)

0.9

Arterial Hypertension

29 (44%)

17 (57%)

12 (33%)

0.06

Dyslipidaemia

30 (45%)

16 (53%)

14 (39%)

0.2

History of CVD

13 (20%)

7 (23%)

6 (17%)

0.5

Aetiology

    

 Aetiology: ALD

16 (24%)

1 (3.3%)

15 (42%)

<0.001b

 Aetiology: HBV

4 (6.1%)

4 (13%)

0 (0%)

0.04b

 Aetiology: AIH

1 (1.5%)

0 (0%)

1 (2.8%)

>0.9

 Aetiology: MASLD

36 (55%)

22 (73%)

14 (39%)

0.005b

 Aetiology: MetALD

8 (12%)

3 (10%)

5 (14%)

0.7

 Aetiology: Others

1 (1.5%)

0 (0%)

1 (2.7%)

>0.9

HVPGa

   

0.004b

 Median (IQR)

16.0 (13.0–18.5)

13.0 (10.0–15.5)

17.0 (15.0–19.0)

 

Child pugha

   

<0.001b

 Median (IQR)

6 (5–8)

5 (5–6)

7 (5–11)

 

MELDa

   

0.007b

 Median (IQR)

9 (7–12)

8 (7–9)

10 (8–15)

 

MELD Naa

   

0.001b

 Median (IQR)

10.0 (7.0–14.0)

8.0 (7.0–10.3)

11.5 (8.0–18.3)

 

Liver elastography by Fibroscana (kPa)

   

0.006b

 Median (IQR)

26 (17–58)

22 (16–32)

62 (22–66)

 

CAPa (dB/m)

   

0.2

 Median (IQR)

287 (222–326)

287 (243–327)

232 (190–313)

 
  1. p values calculated using Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test, or Fisher’s Exact Test for Count Data with simulated p value (based on 2000 replicates).
  2. BMI Body Mass Index, INR International Normalized Ratio, CVD cardiovascular disease, ALD alcoholic liver disease, HBV Hepatitis B Virus, AIH autoimmune hepatitis, MASLD metabolic dysfunction-associated steatotic liver disease, METALD metabolic and alcoholic liver disease, HVPG hepatic venous pressure gradient, MELD Model of end-stage liver disease, MELD Na extended model of end-stage liver disease, CAP controlled attenuation parameter.
  3. aContains missing data.
  4. bSignificant (p < 0.05).
Back to article page